Editas Medicine (EDIT) Receives a Hold from RBC Capital
RBC Capital analyst Luca Issi has maintained a Hold rating on Editas Medicine (EDIT) with a price target of $4.00, while the stock closed at $2.52. The analyst consensus for Editas is also a Hold, with a price target of $3.95, indicating a potential upside of 56.75%. Barclays has similarly rated the stock as Hold with a $3.00 price target. Issi has an average return of 6.7% and a success rate of 41.16% on his recommendations.
In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Editas Medicine, with a price target of $4.00. The company’s shares closed yesterday at $2.52.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Issi covers the Healthcare sector, focusing on stocks such as uniQure, Alnylam Pharma, and Ionis Pharmaceuticals. According to TipRanks, Issi has an average return of 6.7% and a 41.16% success rate on recommended stocks.
Editas Medicine has an analyst consensus of Hold, with a price target consensus of $3.95, implying a 56.75% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $3.00 price target.
